Clear Perspective Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Clear Perspective Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	$220K	Buy	+1,000	New	+$194K	0.07%	164

Other funds holding VRTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Clear Perspective Advisors's VRTX Position: Q4 2021 in Review

Clear Perspective Advisors opened a new position in Vertex Pharmaceuticals (VRTX) in Q4 2021: 1,000 shares worth $220K. The stake represents 0.07% of the portfolio and ranks #164 among its holdings.

1,034 funds tracked by Wall St. Rank hold VRTX as of Q4 2021.

Clear Perspective Advisors held 1,000 shares of Vertex Pharmaceuticals worth $220K as of Q4 2021.
Vertex Pharmaceuticals was a new Clear Perspective Advisors position in Q4 2021.
Vertex Pharmaceuticals made up 0.07% of Clear Perspective Advisors's portfolio in Q4 2021, its #164 holding.
1,034 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2021.

Based on Clear Perspective Advisors's 13F filing for Q4 2021, filed 17 Feb 2022.